Menu Search
Equities

EKF Diagnostics Holdings PLC

LYF:FRA

EKF Diagnostics Holdings PLC

Actions
  • Price (EUR)0.32
  • Today's Change0.002 / 0.63%
  • Shares traded--
  • 1 Year change+3.90%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 20:41 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

EKF Diagnostics Holdings plc is a United Kingdom-based diagnostics company. The Company is engaged in point-of-care testing, central laboratory tests, enzyme manufacturing and the provision of contract manufacturing services to the healthcare industry. Its principal activity is the development, manufacture and supply of products into the in-vitro diagnostics marketplace. Its point of care analyzers is designed for use within doctors' surgeries, clinics, blood banks and hospital and private laboratories to provide results. Its life sciences specialize in producing enzymes and contracted custom products for use in medical diagnostics, pharmaceuticals and industry. Its life science facilities are based in two locations in Indiana, United States. Its central laboratory division manufactures a spectrum of reagents for use in hospital laboratories. Its contract manufacturing business provides specialized services to the diagnostics and healthcare industries for the production of custom kits.

  • Revenue in GBP (TTM)50.95m
  • Net income in GBP4.78m
  • Incorporated2002
  • Employees309.00
  • Location
    EKF Diagnostics Holdings PLCAvon HSE, 19 Stanwell RoadPENARTH CF64 2EZUnited KingdomGBR
  • Phone+44 292 071 0570
  • Fax+44 292 070 5715
  • Websitehttps://www.ekfdiagnostics.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.